Btg medical assessment: the investigator, named the event as reild, radio embolisation induced liver disease, that is a life-threatening liver damage characterised by jaundice and ascites developing 4-8 weeks after treatment, with pathologic changes consistent with vod in the most severe cases.In the edc (electronic data capture) did not document the biology and clinical data (ascites, encephalopathy, child score, bclc).Adverse event assessment: reild (radiation induced liver disease) severity: grade 4; serious event - lead to death; anticipated events; related to device.No device malfunction was reported and no corrective and preventive action (capa) plan has been unidentified.The lot number associated with the therasphere administration was not reported, therefore no investigation could be performed.If additional information becomes available, a follow up report will be submitted.No other information is available that could confirm/deny the alleged event.At this time this report is considered final.
|
Auto-notification received from datatrak 12-mar-2020 for a patient enrolled on the (b)(6)study pt: (b)(6) is a (b)(6) old male patient.Weight: (b)(6) kg.Main comorbidities: arterial hypertension; alcohol intake history; tobacco intake history.Diagnosed with hcc (b)(6) 2016.2-4 lesions - right and left segments.Location of index lesion = vi.Pvt present - yes (tumoural) no extra hepatic disease.Prior anti-cancer therapy: loco regional liver treatment(s) = 2.Ablation: rfa, microwave or cryo.Event: on (b)(6) 2019, patient was administered 3.225 gbq of therasphere in the right liver.On (b)(6) 2019, patient was admitted to the hospital with hepatitis decompensation with ascites and jaundice at 1-month post-radio-embolisation.Further, ascites and pleural effusion apparition with repeated paracentesis has been reported.On (b)(6) 2019, radio-induced liver disease was reported.Seriousness criteria - led to a death on (b)(6) 2019.The investigator has listed the causality probably related to the administration procedure and to the device.Sae assessed by investigator: related to administration procedure: probably.Related to therasphere device: probably.This event is part of a clinical trial registry and was not reported to btg in 2019 the reported events are known adverse events listed in the ifu/risk management documentation.
|